Quick Answer
Atara Biotherapeutics, Inc. reported Net Income Loss of $32.69 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed an increase of +138.3% in Net Income Loss from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), Atara Biotherapeutics, Inc.'s Net Income Loss has grown by 472.6%.
- Historical annual values: Fiscal year 2025: $32.69 million | Fiscal year 2024: -$85.40 million | Fiscal year 2023: -$276.13 million | Fiscal year 2022: -$228.30 million | Fiscal year 2021: -$340.14 million | Fiscal year 2020: -$306.62 million | Fiscal year 2019: -$290.98 million | Fiscal year 2018: -$230.70 million | Fiscal year 2017: -$119.49 million | Fiscal year 2016: -$79.05 million | Fiscal year 2015: -$57.22 million | Fiscal year 2014: -$28.01 million | Fiscal year 2013: -$8.77 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: